Doench, John G.

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science

CRISPR and Genetic EngineeringChromatin Remodeling and Cancer

Cited by 5,234

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology

CRISPR and Genetic EngineeringRNA Interference and Gene Delivery

Cited by 4,637

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell

Gene expression and cancer classificationBioinformatics and Genomic Networks

Cited by 3,515

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature

Ferroptosis and cancer prognosisCancer, Lipids, and Metabolism

Cited by 2,011

Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation

Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014) · Nature Biotechnology

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 1,617

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,147

Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities

Sanson, K. R., Hanna, R. E., Hegde, M., Donovan, K. F., Strand, C., Sullender, M. E., Vaimberg, E. W., Goodale, A., Root, D. E., Piccioni, F., et al. (2018) · Nature Communications

CRISPR and Genetic EngineeringChromatin Remodeling and Cancer

Cited by 1,043

A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis

Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., et al. (2019) · Nature Communications

Ferroptosis and cancer prognosisCancer, Hypoxia, and Metabolism

Cited by 887

Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer

Computational Drug Discovery MethodsCancer Cells and Metastasis

Cited by 878

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersChromatin Remodeling and Cancer

Cited by 852

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 735

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature

Cancer Immunotherapy and BiomarkersRNA regulation and disease

Cited by 697

Mutational processes shape the landscape of TP53 mutations in human cancer

Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics

Cancer-related Molecular PathwaysCancer Genomics and Diagnostics

Cited by 556

Am I ready for CRISPR? A user's guide to genetic screens

Doench, J. G. (2018) · Nature Reviews Genetics

CRISPR and Genetic EngineeringChromatin Remodeling and Cancer

Cited by 452

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersEpigenetics and DNA Methylation

Cited by 370

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell

Cell death mechanisms and regulationChronic Lymphocytic Leukemia Research

Cited by 361

Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs

Listgarten, J., Weinstein, M., Kleinstiver, B. P., Sousa, A. A., Joung, J. K., Crawford, J., Gao, K., Hoang, L., Elibol, M., Doench, J. G., et al. (2018) · Nature Biomedical Engineering

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 336

Massively parallel assessment of human variants with base editor screens

Hanna, R. E., Hegde, M., Fagre, C. R., DeWeirdt, P. C., Sangree, A. K., Szegletes, Z., Griffith, A., Feeley, M. N., Sanson, K. R., Baidi, Y., et al. (2021) · Cell

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 316

Massively parallel assessment of human variants with base editor screens

Hanna, R. E., Hegde, M., Fagre, C. R., DeWeirdt, P. C., Sangree, A. K., Szegletes, Z., Griffith, A., Feeley, M. N., Sanson, K. R., Baidi, Y., et al. (2020) · Cell

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 314

Cas9 activates the p53 pathway and selects for p53-inactivating mutations

Enache, O. M., Rendo, V., Abdusamad, M., Lam, D., Davison, D., Pal, S., Currimjee, N., Hess, J., Pantel, S., Nag, A., et al. (2020) · Nature Genetics

CRISPR and Genetic EngineeringCancer-related Molecular Pathways

Cited by 285

Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens

Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology

CRISPR and Genetic EngineeringRNA Interference and Gene Delivery

Cited by 279

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells

Kahn, J. D., Miller, P. G., Silver, A. J., Sellar, R. S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., et al. (2018) · Blood

Protein Tyrosine PhosphatasesAcute Myeloid Leukemia Research

Cited by 225

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 218

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife

Lung Cancer Treatments and MutationsGenomics, phytochemicals, and oxidative stress

Cited by 160